Background/Aims The World Health Organization set the goal of eliminating hepatitis C virus (HCV) by 2030, with 80% and 65% reductions in HCV incidence and mortality rates, respectively. We aimed to evaluate the health benefits, cost-effectiveness and return on investment (ROI) of HCV elimination.
Methods Using an HCV transmission compartmental model, we evaluated the benefits and costs of different strategies combining screening and treatment for Chinese populations. We identified strategies to achieve HCV elimination and calculated the incremental cost-effectiveness ratios (ICERs) per disability-adjusted life year (DALY) averted for 2022–2030 to identify the optimal elimination strategy. Furthermore, we estimated the ROI by 2050 by comparing the required investment with the economic productivity gains from reduced HCV incidence and deaths.
Results The strategy that results in the most significant health benefits involves conducting annual primary screening at a rate of 14%, re-screening people who inject drugs annually and the general population every five years, and treating 95% of those diagnosed (P14-R4-T95), preventing approximately 5.75 and 0.44 million HCV infections and deaths, respectively, during 2022–2030. At a willingness-to-pay threshold of $12,615, the P14-R4-T95 strategy is the most cost-effective, with an ICER of $5,449/DALY. By 2050, this strategy would have a net benefit of $120,997 million (ROI=0.868).
Conclusions Achieving HCV elimination in China by 2030 will require significant investment in large-scale universal screening and treatment, but it will yield substantial health and economic benefits and is cost-effective.
Citations
Citations to this article as recorded by
Overcoming barriers to HCV screening in Latin America: From evidence to action Javier Crespo, Jose Luis Calleja, Ezequiel Ridruejo, Marta Alonso-Peña, Joaquín Cabezas, Graciela Elia Castro-Narro, Nelia Hernandez, Hugo Cheinquer, Fernando Contreras, Christie Perelló, Manuel Mendizabal, Fernando Cairo, Mário Guimarães Pessôa, Eduardo Annals of Hepatology.2026; 31(2): 102189. CrossRef
Global Advances in Hepatocellular Carcinoma Research and Therapy in 2025 Bo Hu, Qiang Gao Cancer Innovation.2026;[Epub] CrossRef
Evaluation of the performance of reverse transcription-recombinase polymerase amplification (RT-RPA) coupled with CRISPR/Cas12a and microfluidics for one-step detection of common HCV genotypes Qiong Wang, Yushu Wang, Tian Jia, Xiaodong Hu, Fuliang Chen Diagnostic Microbiology and Infectious Disease.2026; 116(3): 117482. CrossRef
Burden and Long-Term Trends of Viral Hepatitis in China: A National and Provincial Analysis Jing-yi Peng, Xin-yu Xiang, Jie Zhang, Yuan Yuan, Yang Ding, Yu-chen Xia, You-de Xiao, Xing-xing He Current Medical Science.2026; 46(3): 828. CrossRef
Resmetirom for noncirrhotic metabolic dysfunction–associated steatohepatitis with liver fibrosis: establishing a value-based price in China, the UK, France, and Germany Andong Li, Meiyu Wu, Yangke Yi, Yongtao He, Chongqing Tan, Xia Luo, Jun Zhang, Xiaomin Wan Expert Review of Pharmacoeconomics & Outcomes Research.2026; : 1. CrossRef
Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe Blessing Dzingirai, Leolin Katsidzira, Maarten J. Postma, Marinus van Hulst, Nyashadzaishe Mafirakureva International Journal of Environmental Research and Public Health.2025; 22(4): 509. CrossRef
Investing in health: Policy lessons from reimbursing direct-acting antivirals for hepatitis C in Taiwan Raoh-Fang Pwu, Wen-Wen Yang, Grace Hui-Min Wu, Sheng-Nan Lu, Rong-Nan Chien Journal of the Formosan Medical Association.2025; 124: S141. CrossRef
First
Prev
